You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesityrelated metabolic diseases constitute a significant public health burdenThe increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obeseIn additionobesity is also associated with accumulation of lipid in the liver parenchymahepat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Novel, Potent and Metabolically Stable Oxytocin Analogues to Treat Obesity

    SBC: Oxt Therapeutics, Inc.            Topic: 300

    The goal of this project is to develop novel oxytocinOXTanalogues with improved safety and efficacy vsnative OXT for the treatment of obesity and related metabolic disordersObesity is an increasing health care burden in the US andeven though it is recognized as a significant risk factor for developing cardiovascular disease and typediabetesthere has been limited progress in developing safe and eff ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A New Small-Molecule Kinase Inhibitor for Airway Disease

    SBC: NuPeak Therapeutics, Inc.            Topic: NHLBI

    Abstract NuPeak Therapeutics Incis a biotechnology companyC corporationdesigned to deliver a first in class smallmolecule kinase inhibitorSMKIfor therapeutic use in humansThe present Project is aimed at an inhibitor for treatment of respiratory airway disease especially due to asthma and COPDwhich remain leading causes of morbidity and mortality in the U Sand worldwide despite current therapeutic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. The Rapid-Production of the High-Performance and Affordable Cadmium Telluride and Cadmium Zinc Telluride for Medical Imaging Applications

    SBC: RADIATION DETECTION TECHNOLOGIES, INC.            Topic: NIBIB

    The high spatial resolution and energy resolution of cadmium zinc tellurideCZTand cadmium tellurideCdTecompared to that of scintillatorsoffers superior image quality in Nuclear medicine and X rayimaging applicationsi eSPECTPETCTBone DensitometryOncologyDental imagingAirportsecurityetcEven after two decades of researchCZT and CdTe remain the desired choice for roomtemperature radiation detectionbut ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists to prevent Charcot Marie Tooth diseaseA Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractCharcot Marie ToothCMTdisease typeA is an incurableprimarily pediatricautosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusinMFNgeneThere are currently no disease altering treatmentsMitochondria in Mot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A mobile technology to extend the reach of primary care for opioid misuse

    SBC: Rissana, LLC            Topic: NIDA

    Project Summary Opioid use disorderOUDhas reached epidemic levels in the United Stateswith catastrophic resultsmore Americans died from opioid overdoses inandthan in the entirety of the Vietnam WarPrimary care providersPCPsserve a critical role in combatting this epidemicbecause they see patients who misuse opioids but are not yet dependent in addition to those who are already dependentHoweverther ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events

    SBC: CAPELLA IMAGING, LLC            Topic: NHLBI

    Despite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. An unique patient population for clinical trials against noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    AbstractNoise is the number one occupational and environmental hazardand noiseinduced hearing lossNIHLis one common form of sensorineural hearing deficitonly second to age related hearing lossCurrently no drug preventing NIHL is approved by the United States Food and Drug AdministrationFDAOne major challenge for the introduction of such interventions is the need to identify appropriate human popul ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government